肺癌组织中半乳糖凝集素1表达与临床病理特征的关系及其预后评估价值分析-东南大学学报医学版

肺癌组织中半乳糖凝集素1表达与临床病理特征的关系及其预后评估价值分析

单位：空军军医大学第二附属医院呼吸与危重症医学科, 陕西西安 710038

分类号：R734.2

出版年·卷·期（页码）：2021·40·第六期（743-749）

摘要：

目的: 探讨肺癌组织中半乳糖凝集素1(Gal-1)表达水平, 分析其与临床病理特征的关系及对预后的评估价值。方法: 选取我院2018年1月至2020年1月收治的130例肺癌患者, 采用免疫组化法检测癌组织、癌旁组织中Gal-1表达情况。收集患者的临床病理资料, 分析Gal-1表达与病理特征的关系。利用Cox多元回归模型分析肺癌预后的危险因素。以术后第1天为起始日、术后随访满12个月为截止时间, 记录患者的总生存率。结果: 肺癌组织中Gal-1阳性表达率为48.46%, 高于癌旁组织的15.38%, 且Gal-1阳性组临床分期Ⅲ期、淋巴结转移、脉管侵犯占比分别为50.79%、57.14%、38.10%, 高于Gal-1阴性组的22.39%、19.40%、16.42%(P < 0.05)。Cox多因素分析提示年龄≥60岁、临床分期Ⅲ期、淋巴结转移、胸膜浸润、脉管侵犯、Gal-1阳性表达是影响患者总生存期、无瘤生存期的危险因素(P < 0.05)。Gal-1阳性组术后12个月的总生存率、无瘤生存率分别为66.67%、63.49%, 低于Gal-1阴性组的88.06%、83.58%(P < 0.05)。结论: 肺癌患者癌组织中Gal-1阳性表达率较高, 其表达可能与临床分期、淋巴结转移、脉管侵犯有关, 有望成为评估预后的重要指标。

Objective: To explore the expression level of galectin-1 (Gal-1) in lung cancer tissues, analyze its relationship with clinical characteristics and its prognostic value.Methods: A total of 130 lung cancer patients admitted to our hospital from January 2018 to January 2020 were selected for research. Immunohistochemistry was used to detect the expression of Gal-1 in cancer tissues and adjacent tissues. The clinicopathological data of patients were collected to analyze the relationship between Gal-1 expression and pathological features. Cox multiple regression model was used to analyze the factors affecting the prognosis of lung cancer patients. From the 1st day after the operation as the starting day to the 12-month follow-up as the cut-off time, the overall survival rate of the patients was recorded.Results: The positive expression rate of Gal-1 in lung cancer tissues was 48.46%, which was higher than 15.38% in the adjacent tissues. In the Gal-1 positive group, the proportions of clinical stage Ⅲ, lymph node metastasis, and vascular invasion were 50.79%, 57.14%, and 38.10, respectively, whitch were higher than 22.39%, 19.40%, 16.42% of Gal-1 negative group (P < 0.05). COX multivariate analysis indicated that age ≥ 60 years, clinical stage Ⅲ, lymph node metastasis, pleural invasion, vascular invasion, and positive expression of Gal-1 were risk factors affecting the overall survival and tumor-free survival of patients (P < 0.05). The overall survival rate and tumor-free survival rate of the Gal-1 positive group were 66.67% and 63.49%, respectively, which were lower than 88.06% and 83.58% of the Gal-1 negative group (P < 0.05).Conclusion: The positive expression rate of Gal-1 in cancer tissues of patients with lung cancer is relatively high, and its expression may be related to clinical staging, lymph node metastasis, and vascular invasion. It is expected to become an important indicator of prognosis.

参考文献：

[1] MCINTYRE A, GANTI A K. Lung cancer—A global perspective[J]. J Surg Oncol, 2017, 115(5): 550-554.
[2] DENES A E, PRESANT C A. Chemotherapy for lung cancer[J]. Brit Med J, 2018, 2(6194): 815-816.
[3] HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
[4] YOUSAF-KHAN U, CARLIJN V, JONG P D, et al. Risk stratification based on screening history: the NELSON lung cancer screening study[J]. Thorax, 2017, 72(9): 819-824.
[5] HUANG J Y, LAROSE T L, LUU H N, et al. Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3)[J]. Int J Cancer, 2020, 146(9): 2394-2405.
[6] HOPKINS J M, EVANS H J. Cigarette smoke-induced DNA damage and lung cancer risks[J]. Nature, 2019, 283(5745): 388-390.
[7] BACIGALUPO M L, CARABIAS P, TRONCOSO M F. Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression[J]. World J Gastroentero, 2017, 23(29): 5266-5281.
[8] CHETRY M, SONG Y, PAN C, et al. Effects of galectin-1 on biological behavior in cervical cancer[J]. J Cancer, 2020, 11(6): 1584-1595.
[9] SETAYESH T, COLQUHOUN S D, WAN Y. Overexpression of galectin-1 and galectin-3 in hepatocellular carcinoma[J]. Liver Res, 2020, 4(4): 173-179.
[10] 陈杰. 病理诊断免疫组化手册[M]. 北京: 中国协和医科大学出版社, 2014: 77.
[11] LUCHINI C, VERONESE N, NOTTEGAR A, et al. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis[J]. Virchows Arch, 2018, 472(6): 939-947.
[12] HELLMANN M D, CIULEANU T E, PLUZANSKI A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. New Engl J Med, 2018, 378(22): 2093-2104.
[13] FORDE P M, CHAFT J E, SMITH K N, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. New Engl J Med, 2018, 378(21): 1976-1986.
[14] DUBE-DELAROSBIL C, ST-PIERRE Y. The emerging role of galectins in high-fatality cancers[J]. Cell Mol Life Sci, 2018, 75(7): 1215-1226.
[15] KOLOBOVNIKOVA Y V, DMITRIEVA A I, JANKOVIC K I, et al. Galectin-1-mediated expression of proteins-regulators of cell cycle and growth factors in gastric cancer[J]. B Siberian Med, 2017, 16(4): 165-172.
[16] CASTAO C A O, MARTINEZ-BOSCH N, GUERRERO P E, et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk[J]. Proc Natl Acad Sci USA, 2018, 115(16): E3769-E3778.
[17] 褚静, 李晓云, 赵娜娜, 等. 半乳糖凝集素-1在神经母细胞瘤组织中的表达及其对细胞增殖和侵袭的影响[J]. 中华实用儿科临床杂志, 2020, 35(22): 1722-1726.
[18] NAM K S, SON S H, OH S, et al. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells[J]. Oncotarget, 2017, 8(22): 35804-35823.
[19] ARCOLIA V, JOURNE F, WATTIER A, et al. Galectin-1 is a diagnostic marker involved in thyroid cancer progression[J]. Int J Oncol, 2017, 51(3): 760-770.
[20] ALICE B, JING Z, HONGBIN C, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis[J]. Cancer Res, 2019, 71(13): 4423-4431.
[21] WANG W, ZHOU Z, XIANG L, et al. CHIP-mediated ubiquitination of galectin-1 predicts colorectal cancer prognosis[J]. Int J Biol Sci 2020, 16(4): 719-729.
[22] 陈雨秋, 周国华, 顾军. 半乳糖凝集素3与乳腺癌的研究进展[J]. 东南国防医药, 2020, 22(5): 68-73.
[23] 张凯恋, 褚倩, 陈元. 非小细胞肺癌抗血管生成药物治疗进展[J]. 医药导报, 2018, 37(5): 546-550.
[24] YOU X L, WANG Y J, WU J et al. Galectin-1 promotes metastasis in gastric cancer through a sphingosine-1-phosphate receptor 1-dependent mechanism[J]. Cell Physiol Biochem, 2018, 51(1): 11-30.
[25] 吴银霞, 周广臣, 牛荃, 等. 半乳糖凝集素-1在膀胱癌中的表达及临床意义[J]. 现代泌尿外科杂志, 2018, 23(4): 259-262.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录